Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV Vaccination and Infectivity Reduction in HPV-positive Women
NCT07303751Phase 2Not yet recruiting
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Bellvitge Institute for Biomedical Research. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT07303751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303751.